---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-001318"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:09.711693+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan

## Summary
- Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).
- Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.
- $25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.
- ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.
- European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025.

## SEC filing metadata
- accession: 0001193805-24-001318
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/0001193805-24-001318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/e663993_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-001318
- JSON: https://secwatch.observer/filing/0001193805-24-001318.json
- Plain text: https://secwatch.observer/filing/0001193805-24-001318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.